AXGN · 10-Q · 2026Q1 · Full report

Product Launch and Transition

Axogen, Inc. · 2026-04-28 · Importance 71 · Surprise 60

On December 3, 2025, the FDA approved the BLA for Avance, Axogen's acellular nerve allograft product, marking a major regulatory milestone. Continued market access depends on verification and description of clinical benefits in confirmatory studies per the approval language. The approval formalizes Avance's position as a core, FDA-approved offering across sensory, mixed and motor peripheral nerve discontinuities and may support expanded hospital adoption and payer coverage. The company continues to list Avance among its principal marketed products alongside Axoguard ECM products and Avive+ Soft Tissue Matrix.